Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 463
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Matthew Craig Kapusta | CEO & Exec. Director | 969.95k | N/A | 1972 |
Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 505.02k | N/A | 1973 |
Mr. Pierre Caloz | Chief Operating Officer | 714k | N/A | N/A |
Dr. Alexander E. Kuta Ph.D. | Chief Regulatory Officer | 649.26k | 1.42M | 1960 |
Dr. Ricardo Dolmetsch Ph.D. | Pres of R&D | 795.35k | N/A | 1969 |
Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | N/A | N/A | N/A |
Mr. David Cerveny | Chief Legal Officer, Gen. Counsel & Sec. | N/A | N/A | 1967 |
Dr. Tamara Tugal Ph.D., MBA | Bus. Devel. Director | N/A | N/A | N/A |
Ms. Erin Boyer | Chief People & Culture Office | N/A | N/A | N/A |
Ms. Maria E. Cantor | Chief Corp. Affairs Officer | N/A | N/A | 1968 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS governance QualityScore as of 28 January 2023 is 3. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 2; Compensation: 3.